GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medtronic, Inc. (MDT) [hlAlert]

Rating:
Mkt Outperform
MDT
up 96.57 %

Medtronic, Inc. (MDT) rated Mkt Outperform with price target $40 by Rodman & Renshaw

Posted on: Wednesday,  Aug 25, 2010  2:25 PM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Medtronic, Inc. (NYSE: MDT) on 08/25/2010. Previously Rodman & Renshaw rated Mkt Outperform Medtronic, Inc. (NYSE: MDT)
on 07/12/2010., when the stock price was $37.40. Since then, Medtronic, Inc. has gained 96.58% as of 08/27/2015's recent price of $73.52.
If you would have followed the previous Rodman & Renshaw's recommendation on MDT, you would have gained 96.57% of your investment in 1872 days.

Medtronic, Inc. (Medtronic) is a global player in medical technology. The Company operates in seven segments that manufacture and sell device-based medical therapies: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Through these seven segments, the Company develops, manufactures and markets its medical devices in more than 120 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The primary markets for products are the United States, Western Europe and Japan. In July 2008, it acquired Restore Medical, Inc. In November 2008, Medtronic acquired CryoCath Technologies Inc. In February 2009, it acquired Ablation Frontiers, Inc. and Ventor Technologies Ltd. In April 2009, Medtronic acquired CoreValve, Inc.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/25/2010 2:25 PM Buy
None
31.85 40.00
as of 12/31/2010
1 Week up  4.19 %
1 Month up  14.85 %
3 Months up  14.68 %
1 YTD up  20.91 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/12/2010 9:25 AM Buy
None
37.40 48.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy